Intellectus Partners LLC Buys 617 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Intellectus Partners LLC raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 30.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,650 shares of the biopharmaceutical company’s stock after acquiring an additional 617 shares during the period. Intellectus Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $1,391,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Brighton Jones LLC increased its position in shares of Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after purchasing an additional 686 shares during the last quarter. DAVENPORT & Co LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $271,000. Keybank National Association OH increased its position in shares of Regeneron Pharmaceuticals by 23.7% during the 1st quarter. Keybank National Association OH now owns 1,533 shares of the biopharmaceutical company’s stock valued at $972,000 after purchasing an additional 294 shares during the last quarter. Private Trust Co. NA increased its position in shares of Regeneron Pharmaceuticals by 13.1% during the 1st quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 19 shares during the last quarter. Finally, World Investment Advisors purchased a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $230,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Trading Down 0.3%

Shares of REGN opened at $651.80 on Monday. The business has a 50-day moving average of $581.80 and a 200 day moving average of $565.38. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $883.15. The firm has a market cap of $69.08 billion, a P/E ratio of 15.61, a price-to-earnings-growth ratio of 2.03 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping the consensus estimate of $9.73 by $2.10. The company had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter last year, the firm posted $12.46 EPS. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Thursday, November 20th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is presently 8.43%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on REGN shares. Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday. Jefferies Financial Group raised their target price on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a research report on Wednesday, August 27th. Rothschild & Co Redburn began coverage on Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They set a “buy” rating and a $890.00 target price for the company. Citigroup lifted their price objective on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Finally, BMO Capital Markets lifted their price objective on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a report on Monday, August 4th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $802.36.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director owned 2,352 shares of the company’s stock, valued at $1,538,843.04. The trade was a 73.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 7.02% of the stock is owned by insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.